Literature DB >> 11689539

Comparing like with like: some historical milestones in the evolution of methods to create unbiased comparison groups in therapeutic experiments.

I Chalmers1.   

Abstract

Histories of clinical trials have recorded and analysed the development of quantification in therapeutic evaluation, the emergence of probabilistic thinking, the application of statistical methods and theory, and the sociology, ethics and politics of clinical trials; but it is surprising that they only rarely identify as a distinct theme the development of efforts to control biases. An exception is Kaptchuk's recent account of the history of blinding and placebos for reducing observer biases. In this complementary paper I introduce and discuss some milestones between 1662 and 1948 in the development of methods to control selection biases when assembling therapeutic comparison groups, to ensure, as far as possible, that 'like is compared with like'. In the paper I note (i) that treatment allocation based on strict alternation abolishes selection bias as effectively as treatment allocation based on strict random allocation; (ii) that use of schedules based on random numbers is more likely to prevent foreknowledge of allocation schedules, and thus the risk of introducing selection bias at the point of recruitment to trials; (iii) that a concern to conceal allocation schedules was the rationale for using schedules based on random numbers in the Medical Research Council trials of vaccination for whooping cough and streptomycin for pulmonary tuberculosis; and (iv) that the introduction of allocation concealment more than half a century ago remains the most recent substantive milestone in the history of efforts to control selection biases in therapeutic experiments.

Entities:  

Mesh:

Year:  2001        PMID: 11689539     DOI: 10.1093/ije/30.5.1156

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  20 in total

1.  Casting and drawing lots: a time honoured way of dealing with uncertainty and ensuring fairness.

Authors:  W A Silverman; I Chalmers
Journal:  BMJ       Date:  2001 Dec 22-29

2.  Evaluating treatment effects reliably.

Authors:  Martin J Landray; Gary Whitlock
Journal:  BMJ       Date:  2002-12-14

3.  Informing participants of allocation to placebo at trial closure: postal survey.

Authors:  Zelda Di Blasi; Ted J Kaptchuk; John Weinman; Jos Kleijnen
Journal:  BMJ       Date:  2002-12-07

4.  The Kendrick-Eldering-(Frost) pertussis vaccine field trial.

Authors:  Harry M Marks
Journal:  J R Soc Med       Date:  2007-05       Impact factor: 5.344

5.  UK Medical Research Council and multicentre clinical trials: from a damning report to international recognition.

Authors:  Iain Chalmers
Journal:  J R Soc Med       Date:  2013-12       Impact factor: 5.344

Review 6.  Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review.

Authors:  Sebastian Straube; Sheena Derry; Henry J McQuay; R Andrew Moore
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

7.  Why the 1948 MRC trial of streptomycin used treatment allocation based on random numbers.

Authors:  Iain Chalmers
Journal:  J R Soc Med       Date:  2011-09       Impact factor: 5.344

8.  Evidence-Based Medicine: A Genealogy of the Dominant Science of Medical Education.

Authors:  Ariane Hanemaayer
Journal:  J Med Humanit       Date:  2016-12

9.  The HAC Trial (Harmonic for Acute Cholecystitis) Study. Randomized, double-blind, controlled trial of Harmonic(H) versus Monopolar Diathermy (M) for laparoscopic cholecystectomy (LC) for acute cholecystitis (AC) in adults.

Authors:  Fausto Catena; Luca Ansaloni; Salomone Di Saverio; Filippo Gazzotti; Federico Coccolini; Antonio Daniele Pinna
Journal:  Trials       Date:  2009-05-26       Impact factor: 2.279

10.  Randomized trials published in some Chinese journals: how many are randomized?

Authors:  Taixiang Wu; Youping Li; Zhaoxiang Bian; Guanjian Liu; David Moher
Journal:  Trials       Date:  2009-07-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.